Last mentioned: Mar 10, 2026
Tenax Therapeutics, ADC Therapeutics, and Rapport Therapeutics released their full-year 2025 financial results, highlighting critical pipeline milestones and cash runway extensions. The reports underscore a pivotal shift toward Phase 3 data readouts and commercial scaling in the specialized biotech sector.
Three distinct biotech players—Tenax, ADC Therapeutics, and Rapport—released 2025 year-end results, highlighting a shift from foundational clinical trials to commercial scaling and late-stage readouts. While Tenax advances its Phase 3 LEVEL trial, ADC Therapeutics focuses on ZYNLONTA’s market penetration and Rapport prepares for key data in epilepsy.
Tenax Therapeutics, ADC Therapeutics, and Rapport Therapeutics reported their full-year 2025 financial results on March 10, 2026, highlighting a period of clinical execution and capital management. The updates underscore the diverging paths of commercial-stage ADC platforms and late-stage cardiovascular and neuroscience pipelines as they navigate the 2026 regulatory landscape.